Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone tablets, 40 mg/12.5 mg and 40 mg/25 mg.
The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India.
Zydus Lifesciences stock rose 1.02 per cent on the NSE to trade at ₹1,101.65 as of 12.19 pm.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.